PARTICULARS TO APPEAR ON THE OUTER PACKAGE {CARTON}

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

PraziTape 50 mg Film-Coated Tablets for Dogs and Cats

Tapewormer

2. STATEMENT OF ACTIVE SUBSTANCES

Each tablet contains 50 mg praziquantel as active substance.

3. PACKAGE SIZE

1 tablet
10 tablets
20 tablets
24 tablets
48 tablets
100 tablets
104 tablets

4. TARGET SPECIES

Dogs and cats

Not for use in dogs or cats weighing less than 2.5 kg.

5. INDICATIONS

For the elimination of tapeworms (including *Echinococcus* spp.) in cats and dogs.

6. ROUTES OF ADMINISTRATION

Oral use.
1 tablet per 10 kg.

7. WITHDRAWAL PERIODS

8. EXPIRY DATE

Exp. {mm/yyyy}

Shelf life after first opening the immediate packaging: use immediately.

9. SPECIAL STORAGE PRECAUTIONS

10. THE WORDS “READ THE PACKAGE LEAFLET BEFORE USE”

Read the package leaflet before use.

11. THE WORDS “FOR ANIMAL TREATMENT ONLY”

For animal treatment only.

12. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”

Keep out of the sight and reach of children.

13. NAME OF THE MARKETING AUTHORISATION HOLDER

Chanelle Pharmaceuticals Manufacturing Ltd

14. MARKETING AUTHORISATION NUMBERS

UK(GB) Vm 08749/5058
UK(NI) Vm 08749/3021

15. BATCH NUMBER

Lot {number}

MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS {BLISTER}

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

PraziTape

2. QUANTITATIVE PARTICULARS OF THE ACTIVE SUBSTANCES

praziquantel: 50 mg/tablet

3. BATCH NUMBER

Lot {number}

4. EXPIRY DATE

Exp. {mm/yyyy}

Shelf life after first opening the immediate packaging: use immediately

PARTICULARS TO APPEAR ON THE PACKAGE LEAFLET:

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

PraziTape 50 mg Film-Coated Tablets for Dogs and Cats

2. COMPOSITION

Each tablet contains 50 mg praziquantel as active substance.

A white to off white film-coated tablet with a breakline on one side.

3. TARGET SPECIES

Dogs and cats

4. INDICATIONS FOR USE

In dogs and cats: treatment of adult tapeworms (immature and mature forms) of the following species:
Echinococcus granulosus
Echinococcus multilocularis
Taenia ovis
Taenia pisiformis
Taenia multiceps
Taenia hydatigena
Taenia taeniaeformis
Dipylidium caninum

5. CONTRAINDICATIONS

Do not use in dogs or cats weighing less than 2.5 kg.
Do not administer to unweaned puppies and kittens.
Do not use in animals with known hypersensitivity to the active substances or to any of the excipients.
Do not use simultaneously with other deworming products without veterinary advice.

6. SPECIAL WARNINGS

FOR ANIMAL TREATMENT ONLY

Special warnings
In order to develop an effective worm control programme local epidemiological information and the risk of exposure of the animal should be taken into account, and it is recommended to seek professional advice, e.g. from a veterinary surgeon or Suitably Qualified Person (registered animal medicines advisor).

It is recommended to treat all the animals living in the same household concomitantly.

Fleas serve as intermediate hosts for one common type of tapeworm-*Dipylidium caninum*.

To avoid reinfection with this parasite, flea control of the animal and its housing should be carried out at the same time. Unless flea control is complete an infected flea population may survive: i.e. re-treatment of the animal may be necessary.

Unnecessary use of antiparasitics or use deviating from the instructions given in the package leaflet may increase the resistance selection pressure and lead to reduced efficacy.

Special precautions for safe use in the target species:
Any part used tablets should be discarded.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:
This veterinary medicinal product may be harmful when ingested, particularly for children.
Avoid accidental ingestion.
The product should be stored in a safe place out of the sight and reach of children.
Any unused part tablets should be discarded.
In the case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician.
Wash hands after administering the veterinary medicinal product

Special precautions for the protection of the environment:
Not applicable

Other precautions:
Echinococcosis represents a hazard for humans. As Echinococcosis is a notifiable disease to the World Organisation for Animal Health (WOAH), specific guidelines on the treatment and follow-up, and on the safeguard of persons, need to be obtained from the relevant competent authority (e. g. experts or institutes of parasitology). If the animal has visited areas where *Echinococcus* spp. are prevalent, a veterinary surgeon should be consulted.

Pregnancy and lactation:
The product can be used during pregnancy and lactation.

Interaction with other medicinal products and other forms of interaction:
Plasma concentrations of praziquantel may be decreased by concomitant administration with drugs that increase the activity of cytochrome P-450 enzymes (e.g. dexamethasone, phenobarbital).

Overdose:
Praziquantel is well tolerated with a wide safety margin. Doses higher than recommended may cause vomiting.

7. ADVERSE EVENTS

Dogs and cats:

Unknown	Vomiting

Reporting adverse events is important. It allows continuous safety monitoring of a product. If you notice any side effects, even those not already listed in this package leaflet, or you think that the medicine has not worked, please contact, in the first instance, your veterinarian. You can also report any adverse events to the marketing authorisation holder using the contact details at the end of this leaflet, or via your national reporting system at:
Website: https://www.gov.uk/report-veterinary-medicine-problem/animal-reacts-medicine
e-mail: adverse.events@vmd.gov.uk

8. DOSAGE FOR EACH SPECIES, ROUTES AND METHOD OF ADMINISTRATION

Oral use.

Dosage:
The minimum recommended dose rate is 5 mg/kg body weight. This corresponds to 1 tablet per 10 kg body weight.

Dogs:

Weight	**Number of Tablets**
Equal to/greater than 2.5 up to 5.0 kg	½ tablet
Greater than 5.0 up to 10.0 kg	1 tablet
Greater than 10.0 up to 20.0 kg	2 tablets
Greater than 20.0 up to 30.0 kg	3 tablets
Greater than 30.0 kg	*pro rata*

Cats:

Weight	**Number of Tablets**
Equal to/greater than 2.5 up to 5.0 kg	½ tablet
Greater than 5.0 up to 10.0 kg	1 tablet
Greater than 10.0 kg	*pro rata*

The need for and frequency of re-treatment should be based on professional advice and should take into account individual risk factors (the local epidemiological situation and the animal's lifestyle).

9. ADVICE ON CORRECT ADMINISTRATION

The tablets are administered as a single dose orally, by opening the animal's mouth and pushing the tablet over the back of the tongue so that it cannot be rejected. Alternatively, a tablet can be wrapped in a piece of meat or butter and offered to the animal or crushed and mixed with the food.

10. WITHDRAWAL PERIODS

Not applicable.

11. SPECIAL STORAGE PRECAUTIONS

Keep out of the sight and reach of children.
This veterinary medicinal product does not require any special storage conditions.
Do not use after the expiry date which is stated on the blister and carton after EXP.
The expiry date refers to the last day of that month.
Shelf life after first opening the immediate packaging: use immediately

12. SPECIAL PRECAUTIONS FOR DISPOSAL

Medicines should not be disposed of via wastewater.
Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any national collection systems applicable to the veterinary medicinal product concerned.

13. CLASSIFICATION OF VETERINARY MEDICINAL PRODUCTS

Veterinary medicinal product not subject to prescription.

14. MARKETING AUTHORISATION NUMBERS AND PACK SIZES

UK(GB) Vm 08749/5058
UK(NI) Vm 08749/3021

Available pack sizes:
Cardboard box containing 1 tablet. (1 blister strip of 1)
Cardboard box containing 10 tablets. (1 blister strip of 10)
Cardboard box containing 20 tablets. (2 blister strips of 10)
Cardboard box containing 24 tablets. (3 blister strips of 8)
Cardboard box containing 48 tablets. (6 blister strips of 8)
Cardboard box containing 100 tablets. (10 blister strips of 10)
Cardboard box containing 104 tablets. (13 blister strips of 8)

Not all pack sizes may be marketed.

15. PID LINK (Do not print heading)

[The following statement must be included where reference to the European Union Product Database is included on the product information. This statement is relevant to both UK(GB) and UK(NI) products:]

Find more product information by searching for the ‘Product Information Database’ on www.gov.uk.

16. CONTACT DETAILS

Marketing authorisation holder and manufacturer responsible for batch release and contact details to report suspected adverse reactions:
Chanelle Pharmaceuticals Manufacturing Ltd
Loughrea
Co Galway
H62 FH90
Ireland

Telephone: +353 (0)91 841788
vetpharmacoviggroup@chanellegroup.ie

For any information about this veterinary medicinal product, please contact the local representative of the marketing authorisation holder.

17. OTHER INFORMATION

NFA-VPS.

For animal treatment only.

Gavin Hall
Approved: 07 October 2026